Unlike general health products stocked in every health store, CJC-1295 moves through a specialist research supply market that Galta residents access almost entirely online. This online-only market structure is actually an advantage for quality — top vendors compete on lab-verified purity in ways no local retailer can match. What genuinely separates top CJC-1295 vendors is complete batch-specific analytical documentation: HPLC for purity, mass spec for identity and weight verification, and endotoxin testing for safety documentation. Use this guide to assess sourcing options methodically — the quality evaluation approach outlined here are universal across all research contexts.
What Studies Say About CJC-1295
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Galta researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
CJC-1295 Purchasing Guide
The most effective path to quality CJC-1295 is community research first — peptide forums aggregate real purchasing experience that are more trustworthy than marketing materials. Mass spectrometry in the COA verifies that the main HPLC peak is actually CJC-1295 and not another compound with similar chromatographic behaviour — HPLC purity alone provides no identity confirmation. For Galta researchers evaluating new suppliers: a test quantity before committing to research volumes before scaling up your order is standard practice in the community. The powdered lyophilised form of CJC-1295 is much more stable than liquid pre-made solutions — lyophilised powder retains potency for years in frozen storage, while liquid preparations break down rapidly even under refrigeration.
Order CJC-1295 — ships to Galta
COA-verified · International tracking · Research grade
CJC-1295 is available for research use only and is not approved for human therapeutic use by the FDA or equivalent agencies worldwide — all information here is provided for educational purposes. Storage requirements for CJC-1295: lyophilised powder at freezer temperature, reconstituted solution refrigerated at 2-8°C and finished within 30 days of reconstitution; reconstitute only with bacteriostatic water. The most significant preventable safety hazard in CJC-1295 research is bacterial endotoxin from low-quality material — a documented endotoxin result in your specific batch certificate is the key safeguard. The research literature on CJC-1295 should be studied thoroughly before planning any study — study methodologies, dosing, and endpoints vary significantly and results do not always generalise across models.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
